Intellipharmaceutics International Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Intellipharmaceutics International Inc.
The US FDA has granted de novo authorization to the Portable Neuromodulation Stimulator from Helius Medical Technologies. The PoNS device, previously given breakthrough status by the agency in May 2020, can improve the gait of patients with multiple sclerosis.
Simplify’s total disc replacement complements NuVasive’s C360 line of cervical repair surgery devices, addressing a market that could eventually be worth $2.6bn.
A strong year is predicted for biopharma business with investment and deal making set to continue apace. Executives across industry share their forecasts for the year ahead.
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
- Generic Drugs
- Controlled Release
- Other Names / Subsidiaries
- Vasogen, Inc.